November 21, 2011 (New York, New York) — Three-year follow-up of the RESILIENT trial has shown that the LifeStent vascular stent (Bard Peripheral Vascular) leads to durable benefits and clinical ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio LAS VEGAS — A repuncturable vascular ...

In patients with common femoral artery disease, balloon angioplasty plus stenting if needed achieves acceptable restenosis and target lesion revascularization (TLR) rates at 1 year. The results render ...

Patients with peripheral arterial disease experienced significantly improved quality of life when treated with the S.M.A.R.T. vascular stent system, according to data presented at VIVA 2013.

Cordis, a unit of Johnson & Johnson ($JNJ) is seeking an expanded indication for its SMART self-expanding stent, and the device performed well in patients with ...

New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery MINNEAPOLIS –– ...

BLOOMINGTON, Ind.--(BUSINESS WIRE)--Cook Medical introduced the results from an aggregated data analysis at the Vascular Interventional Advances (VIVA) conference, highlighting the Zilver ® PTX ® Drug ...

The FDA today approved Cook Medical's Zilver PTX stent. It is the first drug-eluting stent (DES) approved for the treatment of peripheral arterial disease (PAD) in the superficial femoral and proximal ...

Stanford researchers implanted a drug-coated, flexible, metal-mesh tube called a drug-eluting stent into the superficial femoral artery in a patient's thigh. Researchers hope the drug coating will ...

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, ...